GB202108827D0 - Novel antibody cancer therapy - Google Patents

Novel antibody cancer therapy

Info

Publication number
GB202108827D0
GB202108827D0 GBGB2108827.3A GB202108827A GB202108827D0 GB 202108827 D0 GB202108827 D0 GB 202108827D0 GB 202108827 A GB202108827 A GB 202108827A GB 202108827 D0 GB202108827 D0 GB 202108827D0
Authority
GB
United Kingdom
Prior art keywords
cancer therapy
novel antibody
antibody cancer
novel
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108827.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intelligent Omics Ltd
Original Assignee
Intelligent Omics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intelligent Omics Ltd filed Critical Intelligent Omics Ltd
Priority to GBGB2108827.3A priority Critical patent/GB202108827D0/en
Publication of GB202108827D0 publication Critical patent/GB202108827D0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
GBGB2108827.3A 2021-06-18 2021-06-18 Novel antibody cancer therapy Ceased GB202108827D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2108827.3A GB202108827D0 (en) 2021-06-18 2021-06-18 Novel antibody cancer therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108827.3A GB202108827D0 (en) 2021-06-18 2021-06-18 Novel antibody cancer therapy

Publications (1)

Publication Number Publication Date
GB202108827D0 true GB202108827D0 (en) 2021-08-04

Family

ID=77050540

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108827.3A Ceased GB202108827D0 (en) 2021-06-18 2021-06-18 Novel antibody cancer therapy

Country Status (1)

Country Link
GB (1) GB202108827D0 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8788444B2 (en) 2008-10-20 2014-07-22 Nottingham Trent University Data analysis method and system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8788444B2 (en) 2008-10-20 2014-07-22 Nottingham Trent University Data analysis method and system

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Oligonucleotide Synthesis: A Practical Approach", 1984, IRL PRESS
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING CO, pages: 1447 - 1676
"Synthetic Biology, Part A", METHODS IN ENZYMOLOGY, vol. 497, 2011, pages 2 - 662
"Synthetic Biology, Part B, Computer Aided Design and DNA Assembly", METHODS IN ENZYMOLOGY, vol. 498, 2011, pages 2 - 500
B. ROEJ. CRABTREEA. KAHN: "DNA Isolation and Sequencing: Essential Techniques", 1996, JOHN WILEY & SONS
D. M. J. LILLEYJ. E. DAHLBERG: "Methods in Enzymology", 1992, ACADEMIC PRESS, article "Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA"
DAVID R. ENGELKEJOHN J. ROSSI, RNA INTERFERENCE, METHODS IN ENZYMOLOGY, vol. 392, 2005, pages 1 - 454
GAHROUDI ET AL., FEBS LETT., vol. 414, 1997, pages 521 - 526
GONG ET AL., PATHOL ONCOL RES., vol. 18, no. 4, October 2012 (2012-10-01), pages 989 - 96
HAMERS-CASTERMAN ET AL., NATURE, vol. 363, 1993, pages 446 - 448
J. M. POLAKJAMES O'D. MCGEE: "Situ Hybridisation: Principles and Practice", 1990, OXFORD UNIVERSITY PRESS
M.R. GREENJ. SAMBROOK: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS
RAMOS-SEVILLANO ET AL., PLOS PATHOG., vol. 12, no. 3, 14 March 2016 (2016-03-14), pages e1005500
RIECHMANN, FEBS LETT., vol. 339, 1994, pages 285 - 290

Similar Documents

Publication Publication Date Title
ZA202005847B (en) Cancer therapy
SG11202101397TA (en) Biomarkers for cancer therapy
IL277861A (en) Axl-specific antibodies for cancer treatment
GB201905780D0 (en) Cancer therapy
IL287554A (en) Therapeutic rna for ovarian cancer
IL289334A (en) Novel cancer antigens and methods
IL289335A (en) Novel cancer antigens and methods
IL289205A (en) Novel cancer antigens and methods
IL289200A (en) Novel cancer antigens and methods
GB202301902D0 (en) Combination therapy for cancer
GB202012331D0 (en) Therapeutic antibodies
IL304200A (en) Combination therapy using an anti-fucosyl-gm1 antibody
IL310605A (en) Antibodies for treating cancer
IL286353A (en) Combinations of iadademstat for cancer therapy
GB202108827D0 (en) Novel antibody cancer therapy
GB202108828D0 (en) Novel cancer therapy
IL304436A (en) Cancer therapy
GB202001963D0 (en) Cancer therapy
GB202000984D0 (en) Cancer therapy
GB202318158D0 (en) Cancer therapy
GB202302018D0 (en) Cancer therapy
GB202218395D0 (en) Cancer therapy
GB202212918D0 (en) Cancer therapy
GB202108677D0 (en) Therapeutic antibodies
GB201901368D0 (en) Cancer therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)